A new meta-analysis of randomized trials finds that the weight loss produced by prescription anti‑obesity drugs often reverses soon after treatment ends, with measurable regain starting as early as eight weeks and continuing through about 20 weeks after stopping medication. The review pooled data from multiple randomized clinical trials and reports consistent weight increases after discontinuation, particularly for drugs that act on GLP‑1 and related pathways. (bmcmedicine.biomedcentral.com)
The effect is strongest for GLP‑1 receptor agonists and GLP‑1/GIP dual agonists — classes that include semaglutide and tirzepatide — which prompt appetite suppression, slower gastric emptying and metabolic changes while active. When those drugs are stopped, their appetite‑suppressing and metabolic effects wane and many patients regain a substantial share of lost weight; in one trial cited by the review, participants who switched from tirzepatide to placebo regained nearly half of their previously lost weight within a year. (bmcmedicine.biomedcentral.com)
Beyond body weight, several reports warn that stopping these medications can erode the cardiometabolic improvements gained on treatment. Analyses and expert commentaries have documented worsening blood‑sugar control and blood pressure after withdrawal, meaning that benefits for diabetes risk factors and cardiovascular markers may diminish when therapy is stopped. These findings underscore that metabolic gains while on treatment are often drug‑dependent. (indiatoday.in)
Real‑world patterns complicate the picture: many patients discontinue GLP‑1 therapy within the first year for financial, side‑effect or access reasons, and a substantial proportion later restart treatment when weight or symptoms return. That churn-stopping, regaining weight, then restarting-creates practical and clinical challenges for long‑term management. (axios.com)
Clinicians and patients should therefore plan weight‑management strategies with these reversals in mind. The researchers and commentators behind these reports call for clearer expectations about treatment duration, structured transition plans if therapy is to be stopped (for example, dose tapering and intensified lifestyle support), and longer follow‑up studies to identify who can maintain benefits after discontinuation. The evidence suggests that, for many people, sustained benefit may require sustained therapy combined with durable lifestyle and behavioural support. (bmcmedicine.biomedcentral.com)
Original Source: https://thecsrjournal.in/impacts-of-discontinuing-weight-loss-medications-revealed-in-new-study/
Category:
Tags:
Publish Date: 2026-03-18 15:36:00
